Findings presented at ACC.23 show XARELTO® plus aspirin provides a 33 percent reduction in acute limb ischemia following LER, with consistent benefit demonstrated at 30 days, 90 days and up to three years Patients who undergo LER are four times more likely to experience acute limb ischemia, which can lead to amputation or death if left untreated[i] XARELTO® is the first and only anticoagulant approved in combination with aspirin for reducing the risk of major thrombotic vascular events* in patients with peripheral artery disease (PAD)
